Arrail Group Valuation
Is I1D undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of I1D when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: I1D (€1.6) is trading below our estimate of fair value (€3.43)
Significantly Below Fair Value: I1D is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for I1D?
Key metric: As I1D is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is I1D's PS Ratio? | |
|---|---|
| PS Ratio | 3.4x |
| Sales | CN¥1.62b |
| Market Cap | CN¥5.57b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.2x |
| Enterprise Value/EBITDA | 108.6x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does I1D's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.7x | ||
SYAB SYNLAB | 1x | 4.4% | €2.5b |
V3V VITA 34 | 0.9x | 3.1% | €72.5m |
FME Fresenius Medical Care | 0.6x | 3.8% | €12.4b |
RHK RHÖN-KLINIKUM | 0.5x | 2.1% | €836.7m |
I1D Arrail Group | 3.4x | 16.0% | €6.5b |
Price-To-Sales vs Peers: I1D is expensive based on its Price-To-Sales Ratio (3.4x) compared to the peer average (1.6x).
Price to Sales Ratio vs Industry
How does I1D's PS Ratio compare vs other companies in the DE Healthcare Industry?
| 1 Company | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
TLIK Arzneiwerk VIDA | 0.08x | n/a | US$4.67m |
| 1 Company | Estimated Growth | Market Cap |
|---|
Price-To-Sales vs Industry: I1D is expensive based on its Price-To-Sales Ratio (3.4x) compared to the European Healthcare industry average (0.7x).
Price to Sales Ratio vs Fair Ratio
What is I1D's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate I1D's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Shandong Weigao Group Medical Polymer
HK$20.1b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.52
7D
-1.0%
1Y
-38.8%
LNA Santé
€244.4m
Engages in the management and operation of health establishments.
2N3
€23.25
7D
-6.1%
1Y
16.0%
Top Glove Corporation Bhd
RM 7.8b
An investment holding company, manufactures, trades in, and sells gloves in Malaysia, Thailand, the People’s Republic of China, and internationally.
5OU
RM 0.98
7D
0.5%
1Y
-82.5%